Long-Acting Dihydropyridines and Their Mechanism of Action and Applications
E-ISSN: 2314-7326
P-ISSN: 2314-7334

Journal of Neuroinfectious Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • JNID, Vol 12(8)
  • DOI: 10.4172/2314-7326.1000349

Long-Acting Dihydropyridines and Their Mechanism of Action and Applications

Deepika Patel




Long-Acting Dihydropyridines and Their Mechanism of Action and Applications

Long-acting dihydropyridines have been appeared to be more secure anti-hypertensive drugs, in portion, since of diminished reflex reactions. This characteristic too makes them more reasonable for angina than short-acting dihydropyridines. Impacts and Contraindications Dihydropyridine CCBs can cause flushing, cerebral pain, over the top hypotension, edema and reflex tachycardia. Baroreceptor reflex enactment of thoughtful nerves and need of coordinate negative cardiac impacts can make dihydropyridines a less alluring choice for steady angina than diltiazem, verapamil or betablockers. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients [1]. Long-acting dihydropyridines have been appeared to be more secure anti-hypertensive drugs, in portion, since of decreased reflex reactions. This characteristic moreover makes them more reasonable for angina than short-acting dihydropyridines. N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents [2]. The cardiac specific, non-dihydropyridine CCBs can cause over the top bradycardia, disabled electrical conduct. Calcium-channel blockers (CCBs) constitute a assorted gather of compounds but are frequently alluded to as a single homogeneous course of sedate and the clinical reactions unpredictably summarized. Indeed inside the dihydropyridine subgroup, there are noteworthy contrasts in definitions, pharmacokinetics, lengths of activity and their impacts on blood weight, heart rate, conclusion organs and the thoughtful apprehensive framework. Potential major risks however were mainly found to be associated with short-acting CCBs [3]. Amlodipine and nifedipine within the gastrointestinal helpful system (GITS) definition are the foremost considered of the once-daily CCBs. Amlodipine has an intrinsically long pharma-cokinetic half-life, though, in contrast, nifedipine has an intrinsically brief half-life but within the GITS detailing the modern conveyance framework permits for once-daily dosing. This article is determined from a orderly survey of the distributed writing in hypertensive patients. The taking after look terms in three primary databases (MEDLINE, Embase, Science Quotation File) from 1990 to 2011 were utilized. Phenylalkylamine  Ca channel blockers  are  moderately specific for the heart muscle, diminish heart muscle O request and invert coronary  vasospasm, and  are  frequently  utilized  to treat angina.  They  need negligible  vasodilatory  impacts compared with  dihydropyridines  then cause less reflex cardiac arrhythmia, creating it participating for treatment of angina, wherever cardiac arrhythmia will be the foremost crucial donor. Later as dilatation is negligible with the  phenylalkylamines the key part of the activity is inflicting negative inotropy. Phenylalkylamines are thought to urge to Ca channels from the intracellular aspect, in spite of the very fact that the prove is to a point integrated [4]. Patients with angina need to be treated with a beta-blocker. Whereas most of the agents listed higher than are comparatively selective, there are extra agents that are thought of as nonselective. These embrace mibefradil, bepridil, flunarizine (BBB) crossing), fluspirilene (BBB crossing) and fendiline [5]. ACCB could also be an alternate once a beta-blocker alone or together with a long nitrate is incapable or contraindicated. Determination of a non-DHP CCB (e.g., diltiazem, verapamil) vs. A long DHP in patients not on a beta blocker could rely on understanding specific  contemplations. On the off probability that a CCB is being thought of in enlargement to treatment with a beta blocker, the long DHP  CCBs  are  favored thanks to the potential for cardiac arrhythmia or chamber. With a non DHP CCB together with a beta blocker. ACCB may additionally be thought of for additional blood weight management and in patients with variation (Prinzmetal) angina. In enlargement, it’s counseled that everyone patients  with coronary supply line malady UN agency furthermore have cleared out  cavum  beat brokenness diabetes need to be treated with an  ACEI  unless contraindicated. Dihydropyridine  (DHP) Ca channel blockers  are  inferred from the atom dihydropyridine and often utilized to decrease general vascular resistance and vas weight. a number of the time after they are utilized to treat angina, the dilatation, and cardiovascular disease will result in reflex cardiac arrhythmia, which might be inconvenient for patients with anemia indications since of the approaching concerning increment in heart muscle O request. Dihydropyridine Ca channel blockers will decline albuminuria in patients with uropathy [6].


1. Nelson M (2010) Drug treatment of elevated blood Pressure. Australian Prescriber 33 (4): 108-12.

2. Felizola SJ, Maekawa T, Nakamura Y, Satoh F, Ono Y, et al. (2014) Voltagegated calcium channels in the human adrenal and primary aldosteronism. J Steroid Biochem Mol Biol 144 (part B): 410-16.

3. Kaplan MD, Rose MD (2000) Major side effects and safety of calcium channel blockers. Chinese Medical & Biological Information.

4. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA (1997) Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels. Annual Review Pharmacol Toxicol 37: 361-96.

5. Bezprozvanny I, Tsien RW (1995) Voltage-Dependent Blockade of Diverse Types of Channel Antagonist Mibefradil . Molecular Pharmacol 48 (3): 540-49. 6. Remuzzi G, Scheppati A, Ruggenenti P (2002) Clinical Practice. Nephropathy in Patients with Type 2 Diabetes. New England J Medicine 346 (15): 1145-51.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 201
  • [From(publication date): 0-0 - Oct 21, 2021]
  • Breakdown by view type
  • HTML page views: 118
  • PDF downloads: 83